Cromohexal, spray 2.8mg/dose 15 ml

Pharmgroup:

anti-allergic agent – stabilizer of mast cell membranes.

Pharmic action:

CromoHexal is a peroallergic, anti-inflammatory drug.

Stabilizer of mast cell membranes. It blocks the entrance of ions into the mast cell, preventing its degranulation and the release of allergy and inflammation mediators (histamine, bradykinin, prostaglandins, leukotrienes and other biologically active substances).

Prevent manifestation of allergic reactions of immediate type.

Pharmacokinetics:

Absorption through the mucous membrane of the eye is negligible. Systemic bioavailability is less than 0.03%. T1/2 is 5-10 minutes.

Indications

Prevention and treatment of acute and chronic allergic keratoconjunctivitis (hay fever, vernal keratoconjunctivitis).

Pharmacological effect

Pharmaceutical group:

antiallergic agent – stabilizer of mast cell membranes.

Pharmaceutical action:

CromoHexal is a perotiallergic, anti-inflammatory drug.

Mast cell membrane stabilizer. Blocks the entry of ions into the mast cell, preventing its degranulation and the release of mediators of allergy and inflammation (histamine, bradykinin, prostaglandins, leukotrienes and other biologically active substances).

Prevents immediate allergic reactions.

Pharmacokinetics:

Absorption through the mucous membrane of the eye is negligible. Systemic bioavailability is less than 0.03%. T1/2 – 5-10 min.

Special instructions

In addition to the above-mentioned adverse reactions, when cromoglycic acid is prescribed for inhalation use, the following are described (cause-and-effect relationship has not been proven): in 1 out of 10 thousand patients – angioedema, bronchospasm, cough, dizziness, dysuria (including increased urination), headache, arthralgia, swelling of the joints, laryngeal edema, lacrimation, nausea, nasal congestion, rash, swelling of the parotid salivary glands, urticaria.

Anemia, exfoliative dermatitis, hemoptysis, hoarseness, myalgia, nephropathy, periarteritis, pericarditis, peripheral neuritis, photodermatitis, polymyositis, pulmonary infiltrates with eosinophilia are observed in 1 in 100 thousand patients. There have been no reports of similar effects using intranasal formulations.

Therapy should be continued throughout the entire period of action of the allergen.

If irritation or burning of the nasal mucosa does not go away or intensifies, discontinuation of treatment is necessary.

Active ingredient

Cromoglicic acid

Composition

Active ingredient:

disodium salt of cromoglycic acid.

Other components:

benzalkonium chloride,

EDTA,

sodium chloride,

sodium dihydrogen phosphate,

sodium monohydrogen phosphate,

sorbitol,

water for injections.

Contraindications

– hypersensitivity to cromoglycic acid or other components of the drug CromoHexal.

Side Effects

Possible: rarely – mild irritation in the nose; very rarely – headache, temporary disturbance of taste perception; in isolated cases – nosebleeds, irritation of the nasal mucosa, swelling of the tongue, larynx, hoarseness, severe generalized anaphylactic reactions with bronchospasm, cough and suffocation.

If there are severe side effects, as well as complaints not listed above, the patient should consult a doctor.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Dr. Gerhard Mann HFP, Germany